HCW Biologics is developing immunotherapy platforms to activate the immune system in order to disrupt the links between aging and disease. Applying its expertise in immunotherapy and protein engineering to the field of cellular senescence, the Company is developing treatments to tackle cancer and other diseases associated with aging.
Status: Publicly traded, IPO 7/20/21 (Nasdaq: HCWB)
Announcement Date: June 2019
Additional Media Coverage
HCW Biologics Inc. Completes $56.0 Million Initial Public Offering
